000			04330nam a22003615i 4500
988			_aSpringer_Medicine_2016
999			_c88142 _d88142 _x1
001			88142
003			ES-MaUEC
005			20230207040625.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			161130s2016 gw | s |||| 0|eng d
020			_a9783319429250
024	7		_a10.1007/978-3-319-42925-0 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRM315 _b2016 EB
245	1	0	_aKetamine for Treatment-Resistant Depression : _bThe First Decade of Progress _cedited by Sanjay J. Mathew, Carlos A. Zarate, Jr.
264		1	_aCham _bSpringer International Publishing _c2016
300			_a1 recurso en línea (XIX, 155 páginas) _b6 ilustraciones, 3 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_a1. History of Ketamine Use and its Clinical Indications -- 2. Basic and Clinical Pharmacology of Ketamine -- 3. Ketamine: Clinical Studies in Treatment-Resistant Depressive Disorders -- 4. Ketamine and Suicidality -- 5. Ketamine: Safety, Tolerability, and Impact on Neurocognition -- 6. Ketamine's Mechanisms of Rapid Antidepressant Activity: Evidence Gleaned from Pre-Clinical Studies -- 7. Ketamine's Mechanisms of Rapid Antidepressant Activity: Evidence Gleaned from Clinical Studies -- 8. Ketamine and Electroconvulsive Therapy -- 9. Beyond Depressive Disorders: Emerging Data for the Use of Ketamine in OCD, PTSD, and Alcohol/Substance Use Disorders.
520			_aThis book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation zketamine-likey fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic molecular targets that lack ketamine's psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamine's rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose. This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamine's rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research. .
650	0	7	_9139882 _aPsicofarmacología _2embne
700	1		_aMathew, Sanjay J. _eeditor literario _9101611 _0Local
700	1		_aZarate, Jr., Carlos A. _eeditor literario _9134410 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-42925-0zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12981461 _b10-10-17 _c08-03-17
942			_2lcc _cLE
945			_g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11603306 _z06-04-17
998			_b06/2020 _dz _eu _feng _ggw _h0